Skip to main
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences Inc is positioned to benefit from several upcoming value inflection points, including preliminary results from the Phase 1b/2a trial of its personalized cancer vaccine, IFx-2.0, which could significantly broaden its addressable patient population. The company has also indicated potential upside from its anti-VISTA mAb candidate (TBS-2025) in combination with a menin inhibitor, with interim results expected to be released in late 2026. Additionally, the recent decline in share price against the backdrop of an overall positive sector performance presents what is viewed as an attractive entry point for investors, reinforcing the company's growth prospects in immuno-oncology.

Bears say

TuHURA Biosciences Inc. is facing significant challenges that contribute to a negative outlook for its stock, primarily due to potential negative clinical results with its personalized cancer vaccine candidate, IFx-2.0, and delays in advancing its pipeline candidates into registrational programs. The company's inability to secure timely regulatory approvals and the competitive landscape surrounding checkpoint inhibitors further exacerbate these concerns, along with the medium-to-long term risk of shareholder dilution. Additionally, the company's shares have experienced a sharp decline of approximately 62% over the past month, contrasting starkly with the broader market index, raising further alarm among investors.

HURA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 2 analysts, HURA has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.